Carlo Croce, a member of the molecular biology and cancer genetics program in The Ohio State University Comprehensive Cancer Center, received the ARC Leopold Griffuel Prize, which honors work that has led to major breakthroughs in the field of cancer. The prize is awarded by the Board of Directors of the French Association for Cancer Research after evaluation by a scientific committee.
Croce, who also is director of human cancer genetics at Ohio State University, received the award earlier this month during the annual meeting of the French Association of Cancer Research in Paris. After accepting the award, he lectured on “Role of microRNAs in Cancer.”
Carlo CroceCroce, who is professor and chair of the department of molecular virology, immunology and medical genetics at the Ohio State College of Medicine, was one of the first researchers to make a case for the genetic basis for cancer through his discovery of the MYC oncogene’s role in Burkitt lymphoma.
He later identified several other genes responsible for the pathogenesis of lymphoma, leukemia and other cancers. Most recently, Croce has been studying the role of small molecules known as microRNAs.
A member of the National Academy of Sciences, Croce has twice been named an Outstanding Investigator by the National Cancer Institute. He is the recipient of numerous honors and prizes.
The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute is one of only 41 NCI-designated Comprehensive Cancer Centers in the United States and the only freestanding cancer hospital in the Midwest. Ranked among the top 20 cancer hospitals in the nation, The James is the 172-bed adult patient-care component of the cancer program at The Ohio State University.
Eileen Scahill, Medical Center Communications
